Background/Objectives: In many cases, the detection of a single lesion could revolutionise patient clinical management; not all localisations, especially those with a low uptake and, consequently, a low Tumour-to-Background Ratio (TBR), are readily detectable using [18F]F-FDG PET/CT. LAFOV-PET offers a potential enhancement in lesion detection, but the proportion of patients who would benefit from its use has yet to be determined. With the present analysis, we aimed to assess which clinical contexts the enhancement in lesion detection could affect the most.Methods: This retrospective study included 764 patients who underwent [18F]F-FDG PET/CT between January and April 2024. Data were obtained through a review of PET/CT reports. Inclusion criteria comprised patients who attended our centre for cancer pathologies or masses of undetermined nature (MUNs) in a staging setting, excluding patients who had undergone a prior [18F]F-FDG PET/CT scan or who had received therapy for any cancer pathology. This analysis focused on the total number of lesions identified, as well as the SUVmax of the lesion with the highest uptake. We analysed the proportion of patients who were within the range of number of lesions between 1 and 2, as well as who had an SUVmax of the lesion with the highest uptake between 2 and 5, either in the whole patient population or in the pathologies with a larger numerosity in the present study.Results: Among the 862 scans analysed, 289 (34%) were found to be negative, while 573 (66%) presented at least one localisation. In total, 4.5% of patients presented both a lesion number of between 1 and 2 and an SUVmax of the lesion with the highest uptake between 2 and 5. Among the malignancies that were the most common in the analysed population, a higher-than-average proportion of patients meeting these criteria were found in melanoma (6.2%), breast cancer (5.9%), and multiple myeloma (4.8%) patients. Conversely, the conditions that presented a lower proportion of patients in this range were suffering from MUNs (4.0%), lung cancer (2.1%), head–neck cancer (2.1%), suspected lymphoma (2.0%), and colon cancer (0.0%).Conclusions: Our analysis shows that almost 1 in 20 patients evaluated at oncological staging with [18F]F-FDG PET/CT could benefit from the increased diagnostic sensitivity offered by LAFOV-PET scanners. These data, although preliminary, support the need for future prospective controlled studies to confirm the actual clinical impact of implementing LAFOV-PET in current practice.
背景/目的：在许多情况下，单个病灶的检测可能彻底改变患者的临床管理；但并非所有病灶（尤其是低摄取且肿瘤背景比（TBR）较低的病灶）都能通过[18F]F-FDG PET/CT轻松检测。长轴向视野PET（LAFOV-PET）为病灶检测提供了潜在的增强效果，但其适用患者比例尚未明确。本研究旨在评估病灶检测能力提升在哪些临床场景中可能产生最大影响。 方法：这项回顾性研究纳入了2024年1月至4月期间接受[18F]F-FDG PET/CT检查的764例患者。数据通过PET/CT报告回顾获取。纳入标准包括因肿瘤性疾病或性质未明肿块（MUNs）在本中心进行分期评估的患者，排除既往接受过[18F]F-FDG PET/CT检查或曾接受任何肿瘤治疗的患者。分析重点关注检测到的病灶总数及最高摄取病灶的SUVmax值。我们统计了全人群及本研究中病例数较多的病种中，符合以下两个条件的患者比例：①病灶数量为1-2个；②最高摄取病灶SUVmax值介于2-5之间。 结果：在分析的862次扫描中，289次（34%）呈阴性，573次（66%）显示至少一处病灶。总体而言，4.5%的患者同时满足病灶数1-2个且最高摄取病灶SUVmax值2-5的条件。在常见恶性肿瘤中，符合该标准的患者比例高于平均水平的有：黑色素瘤（6.2%）、乳腺癌（5.9%）和多发性骨髓瘤（4.8%）。相反，符合条件患者比例较低的疾病包括：性质未明肿块（4.0%）、肺癌（2.1%）、头颈癌（2.1%）、疑似淋巴瘤（2.0%）及结肠癌（0.0%）。 结论：我们的分析表明，在接受[18F]F-FDG PET/CT肿瘤分期评估的患者中，约每20人就有1人可能受益于LAFOV-PET扫描仪提升的诊断灵敏度。这些数据虽属初步结果，但支持未来开展前瞻性对照研究，以确认LAFOV-PET在当前临床实践中的实际应用价值。
肿瘤(癌症)患者之家